Preferred Label : Anti-TNFR2 Monoclonal Antibody SIM1811-03;
NCIt definition : A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against tumor necrosis
factor receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B),
with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities
Upon administration, anti-TNFR2 monoclonal antibody SIM1811-03 targets and binds to
TNFR2 expressed on immune suppressive cells, such as tumor-associated regulatory T-cells
(Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment
(TME). This induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent
cellular phagocytosis (ADCP), and depletes these TNFR2-expressing immune suppressive
cells. Also, SIM1811-03 prevents the activation of TNFR2 by endogenous tumor necrosis
factor (TNF) and TNFR2-mediated signaling, blocks the activation of the nuclear factor
kappa B (NF-kB) signaling pathway, halts TNFR2-mediated immunosuppression, thereby
inhibiting the proliferation and function of Tregs and enhancing cytotoxic T-cell-mediated
anti-tumor immune responses. In addition, SIM0235 is able to bind to TNFR2 expressed
on the surface of tumor cells, thereby killing TNFR2-expressing tumor cells directly.
TNFR2, a member of the TNFR family of co-stimulatory molecules, plays a role in tumor
necrosis factor signaling, tumor expansion and survival. It is primarily expressed
on the surface of tumor cells and suppressive immune cells in the TME, but rarely
in normal human tissues or peripheral immune cells.;
Molecule name : SIM-0235; SIM1811-03; SIM 0235; SIM1811 03;
NCI Metathesaurus CUI : CL1905190;
Origin ID : C191777;
UMLS CUI : C5784725;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
